PCM
LSTA icon

PenderFund Capital Management’s Lisata Therapeutics LSTA Stock Holding History

PenderFund Capital Management’s Portfolio LSTA Stock Details LSTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-47,500
Closed -$238K – 256
2026
Q1 		$238K Buy
+47,500
New +$196K 0.04% 128

Other funds holding LSTA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.57B AUM 67.1% 1-Year Est. Return
DAM
Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return
RC
Rangeley Capital New Canaan, Connecticut $109M AUM 97.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
GS
GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

PenderFund Capital Management's LSTA Position: Q2 2026 in Review

PenderFund Capital Management sold out of Lisata Therapeutics (LSTA) in Q2 2026, closing a stake of 47,500 shares — an estimated $238K sold.

PenderFund Capital Management first reported a position in LSTA in Q1 2026 and held it in 1 quarter. The position peaked at $238K in Q1 2026. 31 funds tracked by Wall St. Rank hold LSTA as of Q2 2026.

  • PenderFund Capital Management reported no remaining Lisata Therapeutics position as of Q2 2026 after selling out during the quarter.
  • PenderFund Capital Management sold 47,500 Lisata Therapeutics shares in Q2 2026, an estimated $238K.
  • PenderFund Capital Management first reported a position in Lisata Therapeutics in Q1 2026 and held it in 1 quarter.
  • PenderFund Capital Management's Lisata Therapeutics position peaked at $238K in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Lisata Therapeutics as of Q2 2026.

Based on PenderFund Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.